A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy In Patients With Completely Resected STAGE IB−IIIA Non-Small Cell Lung Cancer
To study the efficacy and safety of the study drug. The study drug Atezolizumab is an antibody that targets PD-L1. It will be compared to FDA approved drugs that are used with non small cell lung cancer.
Non small cell lung cancer
18 years of age and older
ECOG status of 0 or 1
18 - 100
Healthy Volunteers Needed
Duration of Participation
Study treatment could last up to 2 years.
Participants that agree to follow up could potentially be followed for 1 year or the rest of their life, depending on which treatment they receive.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
F. Hoffmann-La Roche Ltd